Chiasma, Inc. (CHMA) Misses Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Chiasma (CHMA) Has Enough Cash To Reach Profitability - Oppenheimer
March 15, 2016 7:48 AM EDTChiasma (NASDAQ: CHMA) reported 4Q15/FY2015, ending the quarter with $148.8M in cash, which Oppenheimer analyst, Christopher Marai, believes is sufficient to fund operations through profitability, assuming US approval. The company also announced total aggregate R&D and SG&A including stock-based comp of $80-88M. No change to Outperform rating or $43 PT.
The Phase-3 "MPOWERED" trial for an EU regulatory submission initiated. EU submission expected 2019. The trial will evaluate the non-inferiority (20% margin) of octreotide capsules to injectable... More
